Lv1
38 积分 2021-02-20 加入
Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow‐up of the multicenter, single‐arm, Phase 2 study
2天前
已完结
Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis
10天前
已完结
Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
21天前
已完结
Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
21天前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
28天前
已完结
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
28天前
已完结
Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial
1个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
1个月前
已完结
Long-Term Changes in Physical Activity Among Cancer Survivors After Concurrent Chemoradiotherapy: A Prospective Study
1个月前
已关闭
皖公网安备34019202002308
